News Releases

November 2021

November 23, 2021 11/23/2021 Takeda’s LIVTENCITY (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

November 1, 2021 11/1/2021 Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report with Tokyo Stock Exchange (TSE) in Line with Revised Corporate Governance Code and Published Corporate Governance related Documents on its website

October 2021

October 28, 2021 10/28/2021 Takeda Announces Acquisition of Own Shares

October 28, 2021 10/28/2021 Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands

October 27, 2021 10/27/2021 Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic Cell Therapies Addressing Solid Tumors

October 21, 2021 10/21/2021 Takeda to Hold Second Quarter FY2021 Earnings Conference Calls

October 8, 2021 10/8/2021 Takeda Sets Terms and Conditions for its 10-Year Yen Denominated Unsecured Senior Bond

October 7, 2021 10/7/2021 FDA Advisory Committee Recommends Use of Investigational Drug Maribavir TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus CMV Infection and Disease Refractory to Treatment With or Without Resistance

October 5, 2021 10/5/2021 Takeda Provides Update on TAK-994 Clinical Program